PharmaEssentia Corp. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Burlington MA United States (2003)

Organization Overview

First Clinical Trial
2009
NCT05129644
First Marketed Drug
2021
ropeginterferon alfa-2b-njft (Besremi)
First NDA Approval
2021
ropeginterferon alfa-2b-njft (Besremi)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PharmaEssentia | PharmaEssentia Corp. | PharmaEssentia Corporation | PharmaEssentia Corporation (Co-Sponsor for USA) | PharmaEssentia (Co-Sponsor for USA) | PharmaEssentia Japan K.K. | PharmaEssentia USA Corporation